Biden admin pauses distribution of J&J vaccines after six out of 7 million report ‘rare and severe’ blood clots
The Biden administration paused the distribution of Johnson & Johnson coronavirus vaccinations on Tuesday after six recipients in the United States developed a “rare and severe” disorder involving blood clots after receiving the vaccine.
According to a statement released by the Centers for Disease Control and Prevention (CDC), six women between the ages of 18 and 48 developed a blood clot within about two weeks of vaccination. One woman died and a second woman has been hospitalized and is in critical condition.
“We are recommending a pause in the use of this vaccine out of an abundance of caution,” The Food and Drug Administration (FDA) wrote on Twitter Tuesday.
6.8 million people in the United States have received the Johnson & Johnson vaccine as of April 12.
“The U.S. CDC & FDA are reviewing data involving 6 reported U.S. cases of a rare & severe type of blood clot in individuals after receiving the vaccine. Right now, these adverse events appear to be extremely rare,” the FDA said.
“I know that the information we are providing today is going to be very concerning for Americans who have already received the Johnson & Johnson vaccine and I want to let you know what we’re doing to learn more and to protect people in the meantime and what you can do to be on the alert,” Dr. Anne Schuchat, principal deputy director of the CDC, said during a Tuesday press conference. “There have been six reports of a severe stroke-like illness linked to low platelet counts.”
“For people who recently got the vaccine within the last couple weeks, they should be aware to look for any symptoms,” Schuchat said. “If you received the vaccine and develop severe headaches, abdominal pain, leg pain or shortness or breath, you should contact your healthcare provider and seek medical treatment.”
“Importantly there are three vaccines available and we are not seeing the clotting events with low platelet counts with the other two vaccines,” Schuchat continued.
Johnson & Johnson said the “safety and well-being of people who use our products” remains the company’s number one priority.
Follow Annaliese Levy on Twitter @AnnalieseLevy